The estimated Net Worth of Michael Terrence Gibbs is at least $12.7 Mille dollars as of 24 February 2024. Mr. Gibbs owns over 29 units of T2 Biosystems Inc stock worth over $311 and over the last 9 years he sold TTOO stock worth over $12,428. In addition, he makes $0 as Vice President e General Counsel at T2 Biosystems Inc.
Sign up
Mr. Gibbs TTOO stock SEC Form 4 insiders trading
Michael has made over 17 trades of the T2 Biosystems Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 29 units of TTOO stock worth $67 on 24 February 2024.
The largest trade he's ever made was exercising 145,719 units of T2 Biosystems Inc stock on 24 February 2022 worth over $335,154. On average, Michael trades about 9,069 units every 85 days since 2016. As of 24 February 2024 he still owns at least 135 units of T2 Biosystems Inc stock.
You can see the complete history of Mr. Gibbs stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Gibbs biography
Michael Gibbs Esq serves as Vice President, General Counsel of the Company. Michael Gibbs, Esq. has served as our Vice President and General Counsel since January 2016. Mr. Gibbs joined our company in December 2014 as Senior Corporate Counsel. From 2011 until he joined our company, Mr. Gibbs was General Counsel for Keystone Dental, Inc., a medical device company focused on dental implants and biomaterials. From 2003 to 2011, Mr. Gibbs was a corporate attorney with the law firm Bingham McCutchen LLP (now Morgan Lewis & Bockius). Prior to joining Bingham McCutchen LLP, he was an officer in the United States Marine Corps, departing with the rank of Major. Mr. Gibbs received his J.D. from Boston College Law School and his B.S. in Political Science from Syracuse University.
How old is Michael Gibbs?
Michael Gibbs is 49, he's been the Vice President e General Counsel of T2 Biosystems Inc since 2016. There are 14 older and 4 younger executives at T2 Biosystems Inc. The oldest executive at T2 Biosystems Inc is John Cumming, 74, who is the Lead Independent Director.
What's Michael Gibbs's mailing address?
Michael's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.
Insiders trading at T2 Biosystems Inc
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ... e Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
What does T2 Biosystems Inc do?
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
What does T2 Biosystems Inc's logo look like?
Complete history of Mr. Gibbs stock trades at T2 Biosystems Inc
T2 Biosystems Inc executives and stock owners
T2 Biosystems Inc executives and other stock owners filed with the SEC include:
-
John McDonough,
Non-Executive Chairman of the Board -
Alec Barclay,
Chief Operating Officer -
John J. Sperzel III, B.Sc.,
Chairman & CEO -
Thomas Lowery,
Chief Scientific Officer -
Alec J. Barclay,
Chief Operations Officer -
Seymour Liebman,
Director -
David Elsbree,
Independent Director -
John Cumming,
Lead Independent Director -
Philip Taylor,
IR Contact Officer -
Robin Toft,
Independent Director -
Ninfa Saunders,
Independent Director -
Thierry Bernard,
Independent Director -
Anthony Pare,
Chief Commercial Officer -
Michael Gibbs,
Vice President, General Counsel -
John Sprague,
Chief Financial Officer -
John Sperzel,
President, Chief Executive Officer, Director -
Brett A. Giffin,
Chief Commercial Officer -
Dr. Aparna Jha Ahuja M.D.,
Chief Medical Officer -
Kelley J. Morgan,
Chief People Officer -
Michael Terrence Gibbs,
VP & Gen. Counsel -
John M. Sprague CPA,
Chief Financial Officer -
Aparna Ahuja,
Chief Medical Officer -
Brett A. Giffin,
Chief Commercial Officer -
Joanne Spadoro,
Chief Operations Officer -
Stanley Lapidus,
Director -
Rahul Dhanda,
SVP of Corporate Development -
Sachs Group Incgoldman Sach...,
-
Shawn Lynch,
Chief Financial Officer -
Joshua H. Bilenker,
Director -
David Harding,
Chief Commercial Officer -
Michael J. Cima,
Director -
Harry W Wilcox,
Director -
Group L.P.Crg Partners Iii ...,
-
Darlene M Deptula Hicks,
Chief Financial Officer -
Stanley N Lapidus,
Director -
Thomas J. Carella,
-
Michael A. Pfaller,
Chief Medical Officer -
Venture Partners V, L.P.Pol...,
-
Sarah O. Kalil,
Chief Operating Officer -
Maurice L Castonguay,
Chief Financial Officer -
Advisors, L.L.C. Mbd,
-
Venture Partners V, L.P.Pol...,
-
Sachs Group Incgoldman Sach...,
-
Alan L Crane,
Director -
Ventures Fund 2004 L P Flag...,
-
Capital Iii Lp Aisling Capi...,
-
Laura Lee Adams,
-
Adrian M Jones,
Director -
Sachs & Co. Llcgoldman Sach...,
-
Group L.P.Crg Partners Iii ...,